T-cell engagers in solid tumors: challenges and emerging strategies
Authors: Forero, Jose; Jani, Ruchi; Zheng, Xena; Jani, Chinmay; Bilusic, Marijo
Source journal: Frontiers in immunology (2026-01-01)
DOI: 10.3389/fimmu.2026.1956728
Abstract
T-cell engagers (TCEs) redirect endogenous T cells toward malignant cells by simultaneously binding a tumor-associated target and a T-cell receptor component, most commonly CD3, thereby inducing immune-synapse formation and cytotoxicity independently of conventional antigen recognition. Although TCEs have transformed the treatment of several hematologic malignancies, their development in solid tumors remain limited by heterogeneous and non-tumor-specific antigen expression, impaired tumor penetration and T-cell trafficking, an immunosuppressive tumor microenvironment, and immune-mediated toxicities. This review examines the structural and mechanistic foundations of TCE activity, including antibody fragment-based constructs, IgG-like bispecific antibodies, T-cell receptor-based engagers, and emerging multispecific platforms. We discuss how molecular size, valency, geometry, epitope location, binding affinity, and pharmacokinetic engineering influence immune-synapse quality, antitumor potency, cytokine release, tissue distribution. Major barrier efficacy, including on-target, off-tumor toxicity, antigen heterogeneity and escape, restricted T-cell infiltration, T-cell exhaustion, and metabolic and immunologic suppression are critically evaluated. The evolving clinical landscape across major solid tumors is reviewed, with emphasis on tebentafusp in metastatic uveal melanoma and tarlatamab in previously treated small-cell lung cancer, illustrating the importance of aligning target biology, molecular format, and dosing strategy. We also address cytokine release syndrome, neurologic toxicity, resistance, and treatment failure and highlight strategies designed to widen the therapeutic window and sustain antitumor activity, including step-up dosing, affinity and avidity tuning, conditional or protease-activated constructs, dual-target and trispecific platforms, localized or genetically encoded delivery, rational combinations, and predictive biomarkers. Together, these advances are positioning TCEs as an increasingly adaptable and durable therapeutic platform for solid tumors.
Related topics
Related open access articles
- Emerging mycotoxins in botanicals: benefit and risk
- A Brief Review on Core/shell Quantum Dots
- In vitro cytotoxicity studies on galactosylated chitosan nanoparticles for the delivery of oridonin to liver
- Separation of Six Lupane-Type Triterpenoid Saponins from Leaves of Acanthopanax gracilistylus by HSCCC with Preparative-HPLC
- Chemical characterization of polyphenol extracts from Andean and industrial Solanum tuberosum tubers and their cytotoxic activity on human hepatocarcinoma cells
- Effects of Stresses on the Growth and Cytotoxicity of Shiga-Toxin Producing Escherichia coli in Ground Beef and Spinach
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.